NCT02052739 - Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2014

Primary Completion Date

May 3, 2015

Study Completion Date

May 3, 2015

Conditions

Super-refractory Status Epilepticus

Interventions

DRUG

SAGE-547

Solution for injection for IV infusion

Trial Locations (17)

10032

Sage Investigational Site, New York

14642

Sage Investigational Site, Rochester

19104

Sage Investigational Site, Philadelphia

27157

Sage Investigational Site, Winston-Salem

27710

Sage Investigational Site, Durham

34239

Sage Investigational Site, Sarasota

35294

Sage Investigational Site, Birmingham

37232

Sage Investigational Site, Nashville

48109

Sage Investigational Site, Ann Arbor

48322

Sage Investigational Site, Detroit

60611

Sage Investigational Site, Chicago

67214

Sage Investigational Site, Wichita

70121

Sage Investigational Site, New Orleans

75251

Sage Investigational Site, Dallas

76504

Sage Investigational Site, Temple

02114

Sage Investigational Site, Boston

02115

Sage Investigational Site, Boston

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY